Gastro-esophageal cancer with HER2-expression (cohort 1). research hub

Phase II study of [68Ga]Ga-ABY-025 PET for non-invasive quantification of HER2-status in solid tumors.

This clinical trial is testing a new whole-body scan called a PET scan using a tracer called 68Ga-ABY-025. Researchers want to see if this scan can accurately measure a protein called HER2 in stomach, gullet, and breast cancers without the need for uncomfortable tissue biopsies.